News

The global and randomised phase III ALEX study met its primary endpoint, demonstrating that Alecensa as an initial (first-line) treatment has decreased the risk of disease worsening or death

The models will predict therapeutic indications and side effects from several drug information sources The invention of the new machine learning models is likely to pave way for

The trial included 60 patients with the mycosis fungoides (MF) variant of CTCL, who were randomized to receive either 0.5% remetinostat gel BID, 1% remetinostat gel QD or

Harvoni was approved for pediatric patients with genotype 1, 4, 5 or 6 chronic HCV infection. Sovaldi was approved for pediatric patients with genotype 2 or 3 chronic

The company intends to provide data from trial evaluating cardiovascular outcomes with sitagliptin (TECOS), which includes prescribing information of sitagliptin-containing medicines. The TECOS trial, which involved 4,724 patients

Under the terms of the license agreement, Immune-Onc will acquire the exclusive global rights to develop and commercialize novel biotherapeutics with applications in cancer immunotherapy and other diseases. 

The data demonstrated that serum phosphorus levels, rickets, growth rates, and other functional outcomes improved with burosumab, and these treatment effects were sustained through 64 weeks of treatment.

HoFH is an inherited disorder, which can result in premature cardiovascular disease due to high levels of LDL cholesterol. Evinacumab is an investigational monoclonal antibody to angiopoietin-like protein

Safinamide is currently under clinical development by Meiji in Japan. Under the agreement, Eisai will obtain exclusive rights to safinamide to market in Japan and to develop and